AbCellera Biologics(ABCL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [16][17] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [17][19] - Operating cash usage for 2025 was approximately $130 million, with total cash and equivalents at $561 million at the end of the year [19][20] Business Line Data and Key Metrics Changes - The company successfully advanced its pipeline, with both ABCL635 and ABCL575 now in clinical testing, and added two new programs, ABCL688 and ABCL386, to its pipeline [7][8] - The cumulative total of molecules that have reached the clinic is now 19, with ABCL635 advancing into the phase 2 portion of its clinical trial [12][13] Market Data and Key Metrics Changes - The company has a strong liquidity position with approximately $700 million available to execute its strategy, including $560 million in cash and equivalents and $140 million in committed government funding [19][20] - The focus on internal programs is expected to lead to lower research fee revenues as the company prioritizes its proprietary pipeline [16] Company Strategy and Development Direction - The company aims to become a vertically integrated clinical-stage biotech, having completed its transition and now focusing on building its pipeline [5][6] - Key priorities for 2026 include delivering top-line readouts for ABCL635 and ABCL575, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ABCL635, with a positive readout from the phase 2 study expected to lead to late-stage development [10][11] - The company is committed to advancing its pipeline and believes it has sufficient liquidity to fund investments well beyond the next three years [20] Other Important Information - The company plans to stop reporting on partner-initiated program starts on a quarterly basis in 2026, focusing instead on its proprietary pipeline [12] - The clinical manufacturing facility is now substantially complete, allowing for better control over the supply chain and improved flexibility [18] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes OX40 ligand has a broad effect on the immune system and is considering combination strategies with external parties [24][25] Question: Oncology-based BMS studies - Management sees opportunities in breast and prostate cancer, particularly for patients experiencing severe hot flashes [29][30] Question: Target engagement data for ABCL635 - The phase I portion of the study will be released alongside the phase II data in Q3, with expectations for safety and target engagement data [34][35] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple programs in clinical development and is confident in its operational capacity [46][48] Question: Decision factors for ABCL575's future development - The decision will largely depend on external factors, including potential partnership opportunities and the competitive landscape [49]